NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $29.02 -0.30 (-1.02%) (As of 11/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alkermes Stock (NASDAQ:ALKS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alkermes alerts:Sign Up Key Stats Today's Range$28.90▼$29.3150-Day Range$25.70▼$30.0852-Week Range$22.90▼$32.88Volume550,117 shsAverage Volume1.82 million shsMarket Capitalization$4.70 billionP/E Ratio14.88Dividend YieldN/APrice Target$35.42Consensus RatingModerate Buy Company OverviewAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More… Media Is Mocking Elon, But Wait Until They See This Demo (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Alkermes Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreALKS MarketRank™: Alkermes scored higher than 89% of companies evaluated by MarketBeat, and ranked 145th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth-34.67% Earnings GrowthEarnings for Alkermes are expected to decrease by -34.67% in the coming year, from $2.25 to $1.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 14.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 14.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.89.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.43% of the float of Alkermes has been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Alkermes has recently increased by 2.73%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.17 Percentage of Shares Shorted10.43% of the float of Alkermes has been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Alkermes has recently increased by 2.73%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.35 News SentimentAlkermes has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,235,622.00 in company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Stock News HeadlinesAlkermes plc (NASDAQ:ALKS) SVP Sells $151,813.20 in StockNovember 28 at 8:34 AM | insidertrades.comCraig C. Hopkinson Sells 58,996 Shares of Alkermes plc (NASDAQ:ALKS) StockNovember 13, 2024 | insidertrades.comMedia Is Mocking Elon, But Wait Until They See This DemoElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 1, 2024 | Brownstone Research (Ad)Insider Selling: Alkermes plc (NASDAQ:ALKS) EVP Sells 10,471 Shares of StockNovember 7, 2024 | insidertrades.comCritical Comparison: Ocular Therapeutix (NASDAQ:OCUL) vs. Alkermes (NASDAQ:ALKS)November 27, 2024 | americanbankingnews.comAlkermes to Participate in Upcoming Investor ConferencesNovember 25, 2024 | prnewswire.comAlkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term GrowthNovember 24, 2024 | seekingalpha.comVincerx Pharma (NASDAQ:VINC) & Alkermes (NASDAQ:ALKS) Critical ComparisonNovember 22, 2024 | americanbankingnews.comSee More Headlines ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.74 on January 1st, 2024. Since then, ALKS shares have increased by 4.6% and is now trading at $29.02. View the best growth stocks for 2024 here. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) announced its earnings results on Wednesday, May, 1st. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.58 by $0.15. Alkermes's quarterly revenue was up 21.8% compared to the same quarter last year. Is Alkermes doing a stock buyback? Alkermes' board approved a stock buyback plan on Thursday, February 15th 2024, which allows the company to buy back $400,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 8.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's leadership believes its stock is undervalued. Does Alkermes have any subsidiaries? Alkermes subsidiaries include Rodin Therapeutics. Who are Alkermes' major shareholders? Top institutional shareholders of Alkermes include Wellington Management Group LLP (7.82%), State Street Corp (5.68%), RTW Investments LP (4.11%) and Pacer Advisors Inc. (2.57%). Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, Blair Curtis Jackson, Craig C Hopkinson, Christian Todd Nichols, Nancy Wysenski and Cato T Laurencin. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/01/2024Today11/30/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$35.42 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+22.0%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$1.95 Trailing P/E Ratio14.88 Forward P/E Ratio12.90 P/E Growth0.97Net Income$355.76 million Net Margins22.15% Pretax Margin22.07% Return on Equity24.92% Return on Assets14.55% Debt Debt-to-Equity Ratio0.22 Current Ratio3.45 Quick Ratio3.03 Sales & Book Value Annual Sales$1.51 billion Price / Sales3.12 Cash Flow$2.25 per share Price / Cash Flow12.92 Book Value$7.99 per share Price / Book3.63Miscellaneous Outstanding Shares161,803,000Free Float153,891,000Market Cap$4.70 billion OptionableOptionable Beta0.47 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:ALKS) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
